Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching between Humira and AVT02 in moderate to severe chronic plaque psoriasis
2019-002911-25Phase 3Completed
- Sponsor
- Alvotech
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Continuous Humira with Switching Humira ↔ AVT02 then AVT02 extension (2 arms). Primary endpoints: Primary pharmacokinetic endpoint, Primary efficacy endpoint and 2 more. Started Feb 2020; status: completed.
02
Drugs
adalimumabAVT02
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2019-002911-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002911-25.